Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Chief Gottlieb Envisions Tiered Mandates For Opioid Training System

Executive Summary

Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.

Related Content

Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority
Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products
US FDA Wants To Know What Doctors Know About Abuse-Deterrent Opioids
US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
State Opioid Prescribing Databases Can Handle US FDA's Needs, Officials Say
FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse
Opioid REMS Revisions Reflect Some, Not All, Stakeholder Concerns
Mandatory Provider Training For Opioids Embraced By PhRMA
Opioid Packaging: Is Non-Inferiority Enough For A New Claim?
FDA's Opioid Programs: After Training, What's The Next Step?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts